Opinion|Videos|May 19, 2026

Ongoing Research With Zongertinib in NSCLC

Zongertinib shows strong tolerance and 70%+ responses in HER2-mutant metastatic NSCLC, with a pivotal Phase III trial versus standard chemo-immunotherapy underway.

Joshua K. Sabari, MD, discusses exploring combination approaches as the next research step with zongertinib in patients with HER2 mutation–positive non–small cell lung cancer. He also discusses how ongoing research is specifically examining the role of zongertinib in patients with HER2 amplification and HER2 overexpression.


Latest CME